For critical left primary coronary conduit (LMCA) disease, coronary supply route sidestep joining has been regarded as the standard choice for revascularization. Nevertheless, percutaneous coronary intervention (PCI) is a safe and effective option for appropriately selected patients with LMCA disease due to the rapid advancement of device technology and adjunctive pharmacology. PCI with drug-eluting stents for LMCA disease is a safe option with comparable long-term endurance rates to coronary conduit sidesteps uniting a medical procedure, particularly in patients with low and moderate anatomic risk, according to a few milestone randomized clinical preliminary studies. Even though it is normal that the new evidence from recent randomized clinical preliminaries will set the rules for years to come, there are still annoying and unresolved issues with the PCI technique and LMCA revascularization. A comprehensive overview of the development of LMCA disease and a report on its management are provided in this paper.
HTML PDFShare this article
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
